Log in

NASDAQ:NBRVNabriva Therapeutics News Headlines

$0.67
-0.01 (-1.47 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.66
Now: $0.67
$0.69
50-Day Range
$0.55
MA: $0.78
$1.14
52-Week Range
$0.49
Now: $0.67
$2.77
Volume2.65 million shs
Average Volume4.21 million shs
Market Capitalization$957.10 million
P/E RatioN/A
Dividend YieldN/A
Beta2.39

Headlines

Nabriva Therapeutics (NASDAQ NBRV) News Headlines

Source:
DateHeadline
WEP Clinical Partners With Nabriva Therapeutics for the Named Patient Supply of XENLETA® (lefamulin)WEP Clinical Partners With Nabriva Therapeutics for the Named Patient Supply of XENLETA® (lefamulin)
finance.yahoo.com - July 7 at 12:50 AM
WEP Clinical Partners With Nabriva Therapeutics for the Named Patient Supply of XENLETA ® (lefamulin)WEP Clinical Partners With Nabriva Therapeutics for the Named Patient Supply of XENLETA ® (lefamulin)
www.businesswire.com - July 6 at 9:49 AM
Nabriva Therapeutics PLC - (NASDAQ:NBRV) Expected to Post Quarterly Sales of $250,000.00Nabriva Therapeutics PLC - (NASDAQ:NBRV) Expected to Post Quarterly Sales of $250,000.00
www.americanbankingnews.com - June 29 at 1:46 AM
Zacks: Brokerages Anticipate Nabriva Therapeutics PLC - (NASDAQ:NBRV) Will Announce Earnings of -$0.15 Per ShareZacks: Brokerages Anticipate Nabriva Therapeutics PLC - (NASDAQ:NBRV) Will Announce Earnings of -$0.15 Per Share
www.americanbankingnews.com - June 27 at 9:14 PM
Nabriva Therapeutics (NASDAQ:NBRV) Lowered to "Sell" at BidaskClubNabriva Therapeutics (NASDAQ:NBRV) Lowered to "Sell" at BidaskClub
www.marketbeat.com - June 25 at 4:24 AM
CONTEPO CRL Is a Blow for Cash-Strapped Nabriva (NBRV), Says AnalystCONTEPO CRL Is a Blow for Cash-Strapped Nabriva (NBRV), Says Analyst
finance.yahoo.com - June 24 at 1:16 AM
Nabriva Therapeutics (NASDAQ:NBRV) Trading Down 7% Following Analyst DowngradeNabriva Therapeutics (NASDAQ:NBRV) Trading Down 7% Following Analyst Downgrade
www.marketbeat.com - June 23 at 6:55 PM
CymaBay Seladelpar Data, And Other News: The Good, Bad And Ugly Of BiopharmaCymaBay Seladelpar Data, And Other News: The Good, Bad And Ugly Of Biopharma
seekingalpha.com - June 23 at 3:15 PM
Is Nabriva Therapeutics plc (NBRV) A Good Stock To Buy?Is Nabriva Therapeutics plc (NBRV) A Good Stock To Buy?
finance.yahoo.com - June 22 at 6:41 PM
Northland Securities Cuts Nabriva Therapeutics (NASDAQ:NBRV) Price Target to $1.50Northland Securities Cuts Nabriva Therapeutics (NASDAQ:NBRV) Price Target to $1.50
www.americanbankingnews.com - June 22 at 9:54 AM
Nabriva Therapeutics (NASDAQ:NBRV) Rating Reiterated by HC WainwrightNabriva Therapeutics (NASDAQ:NBRV) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - June 22 at 7:37 AM
Nabriva strikes out again on FDA nod for fosfomycinNabriva strikes out again on FDA nod for fosfomycin
seekingalpha.com - June 20 at 1:46 PM
FDA Again Declines Approval of Nabrivas Antibiotic for Urinary Tract InfectionsFDA Again Declines Approval of Nabriva's Antibiotic for Urinary Tract Infections
www.nytimes.com - June 20 at 8:46 AM
Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for CONTEPO™ (fosfomycin) for injectionNabriva Therapeutics Receives Complete Response Letter from FDA on NDA for CONTEPO™ (fosfomycin) for injection
finance.yahoo.com - June 20 at 12:10 AM
FDA expects to rule on King of Prussia biopharm firms new drug candidateFDA expects to rule on King of Prussia biopharm firm's new drug candidate
www.bizjournals.com - June 17 at 5:27 PM
Nabriva Therapeutics PLC - (NASDAQ:NBRV) Receives Consensus Rating of "Hold" from BrokeragesNabriva Therapeutics PLC - (NASDAQ:NBRV) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - June 16 at 3:09 AM
Stock Traders Purchase High Volume of Nabriva Therapeutics Call Options (NASDAQ:NBRV)Stock Traders Purchase High Volume of Nabriva Therapeutics Call Options (NASDAQ:NBRV)
www.americanbankingnews.com - June 16 at 2:04 AM
Hedge Fund Sentiment Is Stagnant On Organovo Holdings Inc (ONVO)Hedge Fund Sentiment Is Stagnant On Organovo Holdings Inc (ONVO)
finance.yahoo.com - June 10 at 5:57 PM
Nabrivas Shares March Higher, Can It Continue?Nabriva's Shares March Higher, Can It Continue?
finance.yahoo.com - June 8 at 8:29 AM
King of Prussia biopharm firm expects $38M from stock sale as it awaits FDA approvalKing of Prussia biopharm firm expects $38M from stock sale as it awaits FDA approval
www.bizjournals.com - June 2 at 4:58 PM
Implied Volatility Surging for Nabriva (NBRV) Stock OptionsImplied Volatility Surging for Nabriva (NBRV) Stock Options
finance.yahoo.com - June 1 at 12:42 PM
Nabriva secures private $38M capital raiseNabriva secures private $38M capital raise
seekingalpha.com - May 30 at 1:01 PM
Nabriva Therapeutics Announces $38 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesNabriva Therapeutics Announces $38 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
finance.yahoo.com - May 29 at 9:53 PM
European advisory group backs Nabrivas lefamulinEuropean advisory group backs Nabriva's lefamulin
seekingalpha.com - May 29 at 11:52 AM
Nabriva Therapeutics Receives Positive EU CHMP Opinion for XENLETA™ (lefamulin) for the Treatment of Community-Acquired Pneumonia (CAP)Nabriva Therapeutics Receives Positive EU CHMP Opinion for XENLETA™ (lefamulin) for the Treatment of Community-Acquired Pneumonia (CAP)
finance.yahoo.com - May 29 at 11:52 AM
Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare ConferenceNabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 27 at 8:08 PM
Nabriva Therapeutics Plc (NBRV) CEO Ted Schroeder on Q1 2020 Results - Earnings Call TranscriptNabriva Therapeutics Plc (NBRV) CEO Ted Schroeder on Q1 2020 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 2:17 AM
Nabriva Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate UpdatesNabriva Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Updates
finance.yahoo.com - May 11 at 4:16 PM
Nabriva Therapeutics to Present at the BofA Securities 2020 Virtual Health Care ConferenceNabriva Therapeutics to Present at the BofA Securities 2020 Virtual Health Care Conference
www.marketwatch.com - May 11 at 8:34 AM
Nabriva Therapeutics to Present at the BofA Securities 2020 Virtual Health Care ConferenceNabriva Therapeutics to Present at the BofA Securities 2020 Virtual Health Care Conference
finance.yahoo.com - May 11 at 8:34 AM
Nabriva Therapeutics to Report First Quarter 2020 Financial Results on May 11, 2020Nabriva Therapeutics to Report First Quarter 2020 Financial Results on May 11, 2020
finance.yahoo.com - May 8 at 6:06 PM
Why Earnings Season Could Be Great for Nabriva Therapeutics (NBRV)Why Earnings Season Could Be Great for Nabriva Therapeutics (NBRV)
finance.yahoo.com - May 7 at 1:36 PM
Nabriva up 11% premarket on publication of positive lefamulin dataNabriva up 11% premarket on publication of positive lefamulin data
seekingalpha.com - May 5 at 10:07 AM
XENLETA® (Lefamulin) Treatment Results in a Rapid Time-to-Clinical Response in Hospitalized Patients with Community-Acquired Bacterial Pneumonia (CABP)XENLETA® (Lefamulin) Treatment Results in a Rapid Time-to-Clinical Response in Hospitalized Patients with Community-Acquired Bacterial Pneumonia (CABP)
finance.yahoo.com - May 5 at 10:07 AM
Why Nabriva Therapeutics (NBRV) Stock Might be a Great PickWhy Nabriva Therapeutics (NBRV) Stock Might be a Great Pick
finance.yahoo.com - April 14 at 1:32 PM
Centers for Medicare & Medicaid Services Issues Product-Specific J-Code for XENLETACenters for Medicare & Medicaid Services Issues Product-Specific J-Code for XENLETA
finance.yahoo.com - April 9 at 9:10 AM
Nabriva Therapeutics to Present at the 19th Annual Needham Virtual Healthcare ConferenceNabriva Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 8 at 8:05 AM
Nabriva (NBRV) Looks Good: Stock Adds 5.7% in SessionNabriva (NBRV) Looks Good: Stock Adds 5.7% in Session
finance.yahoo.com - April 2 at 3:37 PM
Nabriva Therapeutics Plc to Host Earnings CallNabriva Therapeutics Plc to Host Earnings Call
www.baystreet.ca - March 12 at 7:13 PM
Nabriva Therapeutics to Report 2019 Financial Results and Recent Corporate Highlights on March 12, 2020Nabriva Therapeutics to Report 2019 Financial Results and Recent Corporate Highlights on March 12, 2020
finance.yahoo.com - March 10 at 7:02 PM
Amicus' (FOLD) Q4 Earnings Miss Estimates, Sales SurpassAmicus' (FOLD) Q4 Earnings Miss Estimates, Sales Surpass
finance.yahoo.com - March 3 at 2:01 PM
Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - March 2 at 5:10 PM
Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) Revenue EPSNabriva Therapeutics plc Ordinary Shares Ireland (NBRV) Revenue EPS
www.nasdaq.com - February 13 at 12:41 AM
Will Nabriva Therapeutics Continue to Surge Higher?Will Nabriva Therapeutics Continue to Surge Higher?
finance.yahoo.com - January 22 at 3:44 PM
BRIEF-Nabriva Gets FDA Acknowledgement Of NDA Resubmission For ContepoBRIEF-Nabriva Gets FDA Acknowledgement Of NDA Resubmission For Contepo
www.msn.com - January 8 at 8:40 PM
FDA accepts Nabrivas refiled Contepo application; shares up 8% after hoursFDA accepts Nabriva's refiled Contepo application; shares up 8% after hours
seekingalpha.com - January 8 at 8:40 PM
Nabriva Therapeutics Receives FDA Acknowledgement of New Drug Application Resubmission for Intravenous CONTEPO™ (fosfomycin) for InjectionNabriva Therapeutics Receives FDA Acknowledgement of New Drug Application Resubmission for Intravenous CONTEPO™ (fosfomycin) for Injection
finance.yahoo.com - January 8 at 8:40 PM
Nabriva takes another shot at getting infection drug approved; raising $20MNabriva takes another shot at getting infection drug approved; raising $20M
finance.yahoo.com - December 20 at 4:59 PM
Nabriva down 20% on equity offeringNabriva down 20% on equity offering
seekingalpha.com - December 20 at 11:58 AM
Nabrivas stock soars after resubmitting NDA for UTI treatmentNabriva's stock soars after resubmitting NDA for UTI treatment
www.msn.com - December 20 at 6:57 AM
This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.